










































Age-related macular degeneration (AMD) is the leading 
cause of vision loss in the elderly in the Western World. 
It is a complex disease as reflected not only by the ever 
growing number of genetic, environmental, and 
systemic risk factors identified to date [1-3], but also 
our improved understanding of the various clinical 
phenotypes, through the advent of high resolution 
imaging modalities used to evaluate both patients and 
post-mortem tissue pathology [4-8]. Clinically, during 
the initial stages of AMD development, known as ‘early  
 
 









































dry’, patients accumulate extracellular lipid and protein 
filled deposits below the retinal pigment epithelial 
(RPE) cell layer [1, 5, 9], which normally serves as 
crucial support to the overlying neural retina and forms 
part of the outer blood retina barrier [10]. These 
deposits can lead to dysfunction and atrophy of RPE 
cells, which along with loss of photoreceptors and 
choroidal endothelial cells, are major steps in AMD 
progression towards severe vision deterioration 
associated with the ‘late dry’ sub-type known as 
geographic atrophy [1, 3, 11]. Advanced exudative or 
‘wet’ AMD is characterized by endothelial invasion 






























and  angiogenic  pathways,  while  ligand  activation  of  PPARβ/δ,  in  vitro,  decreased  RPE  lipid  accumulation,
characteristic of dry AMD. This study demonstrates for the first time, selective regulation of a nuclear receptor
in  the  eye  and  establishes  that  selective  targeting  of  PPARβ/δ may  be  a  suitable  strategy  for  treatment  of
different clinical sub‐types of AMD. 
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through Bruch’s membrane and pathological growth of 
abnormal new vessels originating from the choroid, 
below the RPE, resulting in the formation of choroidal 
neovascular (CNV) lesions, which are responsible for 
the most severe form of disease-related vision loss [1, 3, 
12]. Demographically, both the increase in life 
expectancy of the general population, and prevalence of 
AMD in the elderly population with age [2, 3], ensures 
that this disease will become an even greater health 
problem in the near future. Therefore, it is imperative to 
investigate the pathological pathways that are altered in 
this complex disease, recognize potential models that 
demonstrate phenotypic features of AMD, and identify 
alternative targets, in order to develop treatments and 
improve the quality of life of patients. Currently there 
are no therapies available for the ‘dry’ forms of the 
disease. However, antibody-based treatments targeting 
vascular endothelial growth factor (VEGF) are offered 
to patients with ‘wet’ AMD, which are effective to 
varying degrees in approximately 30-60% of the 
patients. This leaves more than 30% of the patient 
population, for which an alternative treatment must be 
found.  
 
Peroxisome proliferator-activated receptors (PPARs) 
are ligand activated transcription factors, which belong 
to the steroid hormone superfamily. Though PPARα, 
PPARβ/δ and PPARγ are ubiquitously expressed 
throughout the body [13, 14], PPARβ/δ has been shown 
to be involved in regulation of pathways important in 
AMD pathogenesis, including lipid metabolism, 
extracellular matrix remodeling, angiogenesis and 
inflammation [1, 15]. Because of this, we hypothesized 
that PPARβ/δ is critical in the etiology of AMD. Here 
we report a novel role of the PPARβ/δ pathway in the 
pathobiology of AMD. We first established the 
expression and activity of the pathway in cell culture 
models of RPE and choroidal endothelial cells, cells 
vulnerable in AMD. Next we evaluated the ocular 
phenotype of aged mice harboring the null allele at the 
PPARβ/δ locus (Pparβ/δ-/-). Finally, we tested the 
therapeutic potential of targeting the PPARβ/δ pathway 
in an experimentally induced model of choroidal 
neovascularization.  Our in vitro studies revealed that 
following PPARβ/δ knockdown there is an increase in 
expression of select extracellular matrix molecules 
concomitant with a decrease in expression of growth 
factors, in both RPE and choroidal endothelial cells. 
Similarly, PPARβ/δ knockdown impacted the 
expression of several AMD-related genes in the 
inflammatory and lipid metabolic pathways. In vivo 
evaluation of eyes from aged wild-type mice showed 
accumulation of thin patchy sub-RPE deposits, while 
genetic ablation of Pparβ/δ in vivo, resulted in increased 
frequency and severity of continuous sub-RPE deposits 
along with development of RPE degenerative changes. 
On the other hand, Pparβ/δ knockout mice develop 
CNV lesions smaller in volume and area, increased 
localization of immune cells, and decreased deposition 
of extracellular matrix molecules, compared to 
Pparβ/δ+/+ mice. Finally, we observed that treatment 
with a PPARβ/δ antagonist, GSK0660, resulted in a 
significant inhibition of neovascular lesion size, and 
extracellular matrix deposition, in aged mice, while 
treatment with a PPARβ/δ agonist resulted in a decrease 
of lipid accumulation in a cell culture model of  ‘lipid 
loaded RPE’ cells. This study establishes a strong basis 
to consider selectively testing and developing, PPARβ/δ 




The PPARβ/δ pathway is biologically active in AMD 
vulnerable cells 
 
The activity of PPARβ/δ in AMD vulnerable cells was 
examined in human primary RPE cells, the human 
derived ARPE19, and the macaque derived RF/6A 
choroidal endothelial cell lines. This was performed by 
examination of the (i) expression of PPARβ/δ and its 
binding partners the retinoid X receptor alpha and beta 
(RXRα and β), (ii) receptor transcriptional activity, by 
measuring the binding of the receptor-ligand complex to 
the gene-response element, and (iii) expression of 
known PPARβ/δ target genes. Freshly isolated human 
RPE cells and choroid from aged donor eyes, along with 
primary human RPE cultured cells, ARPE19 and RF/6A 
cell lines, expressed PPARβ/δ and its binding partners 
the RXRs (Figure 1A). Additionally, ligand activation of 
PPARβ/δ with GW0742 (10μM) caused increased 
transcriptional activity in human primary RPE (Figure 
1B), RF/6A cells (Figure 1C) and ARPE19 cells (Figure 
S1) [16]. These changes were mitigated by the PPARβ/δ 
antagonist, GSK0660 (10μM), and siRNA-mediated 
knockdown of PPARβ/δ (Figure 1, B and C). Similarly, 
ligand activation of PPARβ/δ increased expression of the 
PPARβ/δ target genes, angiopoietin-like 4 (ANGPTL4) 
and pyruvate dehydrogenase kinase, isozyme 4 (PDK4), 
in primary RPE cells (Figure 1, D and E), RF/6A cells 
and ARPE19 cells (Figure 1, F, G, S1 and S2), an effect 
that was diminished by treatment with a PPARβ/δ 
antagonist or PPARβ/δ knockdown.  
 
Loss of PPARβ/δ results in selective regulation of 
dry and wet AMD related pathogenic pathways 
 
The discovery of multiple genetic, systemic, and 
environmental risk factors associated with AMD 
ontology has resulted in the identification of several 
AMD-pathogenic pathways. These pathways include, 
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but are not limited to, impairment of extracellular 
matrix turnover [3, 17], increased angiogenesis [18], 
inflammation [19, 20], and dysregulation of lipid 



















































PPARβ/δ pathway has been shown to regulate collagen 
synthesis in vitro and in vivo [22-24], the effect of 
PPARβ/δ knockdown (siPPARβ/δ) on the expression of 























































cells  [hR], ARPE19  cells  [A],  human  choroid  [hC],  and RF/6A  cells  [C],  36B4 was  used  as  loading  control.  PPARβ/δ  activity  in
primary RPE  (1°RPE) cells  (B) and RF/6A cells  (C)  transfected with  the DR1  luciferase reporter and siC or siPPARβ/δ; cells were
treated with PPARβ/δ agonist, GW0742  (10μM) or antagonist, GSK0660  (10μM) or DMSO as vehicle control  (n = 3): a: p < 0.05
relative  to  DMSO  treated  cells;  b:  p < 0.05  relative  to  drug+siC  treated  cells  (p  <   0.05;  two  way  ANOVA,  Sidak’s multiple
comparisons test). Expression of ANGPTL4 and PDK4 mRNA in primary RPE (1°RPE) cells (D and E) and RF/6A (F and G) in siC and
siPPARβ/δ  (100 pmoles/250,000 cells) treated cells  in response to GW0742, GSK0660, or DMSO as a control  (n = 3); a: p < 0.05
relative to DMSO treated cells; b: p < 0.05 relative to drug+siC treated cells (Two way ANOVA, Sidak’s multiple comparisons test).
  



















































































































significant,  two  way  ANOVA,  Sidak’s  multiple  comparisons  test);  siC,  control  siRNA;  siPPARβ/δ,  PPARβ/δ  siRNA.  Quantification  of
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Deletion of PPARβ/δ expression caused upregulation of 
collagen type 1A1 (COL1A1) and vitronectin (VTN) in 
human primary RPE cells, and no significant effect on 
expression levels of collagen type 4A4 (COL4A4) and 
fibronectin (FN1) (Figure 2A). In RF/6A cells, deletion 
of PPARβ/δ resulted in downregulation of the 
extracellular matrix genes COL1A1, COL4A4 and FN1 
(Figure 2B). Increased deposition of collagen type 1A1, 
collagen 4A4 and vitronectin is characteristic of 
Bruch’s membrane and human sub-RPE deposits 
typically observed in dry AMD [25], while endothelial 
cells require extracellular matrix molecules such as 
COL4A4, for pericyte recruitment and vessel 
stabilization during angiogenesis [26, 27]. These results 
demonstrate selective roles for PPARβ/δ in AMD 
vulnerable cells suggesting it regulates extracellular 
matrix turnover in RPE cells similar to that reported for 
dry AMD, yet inhibits an angiogenic phenotype in 
endothelial cells. Evaluation of the expression of growth 
factors that regulate vessel stabilization following 
PPARβ/δ knockdown confirmed this variability in AMD 
vulnerable cells. A significant decrease in the 
expression of platelet-derived growth factor receptor 
beta (PDGFRB), vascular endothelial growth factor A 
(VEGFA) and transforming growth factor beta 1 
(TGFB1) in both primary RPE and RF/6A cells 
transfected with siPPARβ/δ, as compared to control 
siRNA (Figure 2, C and D) suggests that disruption of 
PPARβ/δ expression in both of these AMD-vulnerable 
cells leads to an anti-angiogenic environment in the 
RPE and choroid. Interestingly, receptor knockdown 
resulted in a downregulation of the expression of the 
neurotrophic agent, pigment epithelial-derived factor 
(PEDF or SERPINF1) in RPE cells but not in RF/6A 
cells (Figure 2, C and D). Since modulation of the 
PPARβ/δ pathway has been shown to regulate 
inflammation in vitro and in vivo, the effect of PPARβ/δ 
knockdown on the expression of molecular markers of 
inflammation was also examined [23, 28, 29]. Genetic 
knockdown of PPARβ/δ resulted in the formation of a 
pro-inflammatory environment in the outer retinal cells, 
which was evident by the upregulation of inflammatory 
genes such as, prostaglandin-endoperoxide synthase 2 
(PTGS2), interleukin-1 beta (IL1B), chemokine ligand 2 
(CCL2) and tumor necrosis factor alpha (TNFA) in RPE 
cells (Figure 2E); and secreted phosphoprotein 1 (SPP1) 
and TNFA in RF/6A cells (Figure 2F).  Given the role of 
PPARβ/δ in regulating lipid processing pathways [30], 
the expression of genes involved in lipid metabolism 
and previously shown to be altered in AMD was 
examined. Increased expression of apolipoprotein E 
(APOE), A (APOA) and low density lipoprotein 
receptor (LDLR) in human RPE cells (Figure 2G), along 
with decreased expression of several lipid transfer genes 
in choroidal endothelial cells (Figure 2H) following 
PPARβ/δ knockdown was observed. Extracellular and 
intracellular accumulation of lipids and lipofuscin are 
characteristics of dry AMD. Good animal models 
demonstrating significant lipid accumulation in Bruch’s 
membrane and/or deposits, and not requiring aging mice 
for long periods of time are currently not available. 
Therefore, in lieu of that, we examined the effect of 
activating or antagonizing PPARβ/δ in an in vitro 
culture model of lipid-loaded RPE cells. Ligand 
activation of PPARβ/δ resulted in a significant decrease 
in RPE lipid accumulation (Figure 2I), suggesting a 
potential therapeutic avenue to pursue in the treatment 
of early dry AMD, in which removal of extra- and intra-
cellular lipids is a goal. Collectively, these data suggest 
that though PPARβ/δ drives several of the pathogenic 
pathways associated with AMD development, it may 
have selective detrimental and beneficial effects in 
AMD vulnerable cells. To determine the role of 
PPARβ/δ on the posterior eye, the ocular phenotype of 
wild-type (Pparβ/δ+/+) and Pparβ/δ-null (Pparβ/δ–/–) 
mice was examined.   
 
Aged Pparβ/δ–/– mice exhibit several phenotypic 
features of dry AMD  
 
Gene specific differences in the weights of 18-month 
old Pparβ/δ+/+ and Pparβ/δ–/– mice were not observed 
(Figure S3). The overall architecture of the retina and 
RPE/choroid was evaluated and no differences in the 
morphology of the inner retina and/or thickness of the 
inner and outer nuclear layers were found (Figure S4). 
In the outer retina, thin patchy sub-RPE deposits were 
observed in both 18-month old Pparβ/δ+/+ and Pparβ/δ–
/– mice with varying degrees of thickness and length 
(Figure 3, A, B, C and D). Detailed quantification of the 
length of deposit relative to length of Bruch’s 
membrane revealed deposits were present at a higher 
frequency in Pparβ/δ–/– mice compared to Pparβ/δ+/+ 
mice (ratio of deposits/BrM length: 0.42 േ 0.02 versus 
0.31 േ0. 03 for Pparβ/δ–/– and Pparβ/δ+/+ mice, 
respectively; Figure 3E; 100% of Pparβ/δ-/- mice 
developed deposits, while only 25% of Pparβ/δ+/+ mice 
developed deposits). Transmission electron microscopy 
was used for further detailed analysis of the ultra-
structure of the RPE-choroid complex. Eighteen-month 
old Pparβ/δ+/+ mice exhibited normal RPE morphology 
with organized basal infoldings (Figure 3F), along with 
some thin continuous “age-related” sub-RPE deposits 
(Figure 3G). By contrast, eyes from age-matched 
Pparβ/δ–/– mice exhibited regions with both normal and 
abnormal RPE morphology. Specifically, the RPE 
degenerative changes observed included hypo- and 
hyper-pigmentation (Figure 3, H, I, J, K and L), loss of 
basal infoldings (Figure 3, J, K and L), thickened 
Bruch’s membrane (0.59 േ0.03 µm versus 
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0.45 േ 0.01 ߤ݉ for Pparβ/δ–/– and Pparβ/δ+/+ mice, 






















































continuous thin and thick sub-RPE deposits (Figure 3, J, 



























































of deposits per Bruch’s membrane  (BrM)  length  in plastic  sections  (mean and S.E.M., n=10  images/animal, n=4/genotype, * p<0.05).
Electron micrographs of RPE/Bruch’s membrane/choroidal junction in 18‐mo‐old Pparβ/δ+/+ mice display (F) normal RPE morphology (G)
with  some  age  related  deposits  (dotted  line),  whereas  18‐mo‐old  Pparβ/δ−/−  mice  show  (H)  RPE  hypo‐pigmentation,  (I)  hyper‐
pigmentation and (J) abnormal basal infoldings with thin sub‐deposits, (K) loss of basal infoldings with thin and (L) thick sub‐RPE deposits
(dotted  line).    (M) Quantification of Bruch’s membrane  thickness  in electron micrographs of Pparβ/δ+/+ and Pparβ/δ−/− mice    (n = 10
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Gene specific differences in the morphology and overall 
structure of the choriocapillaries, including fenestration 
of the vessels, were not noted (Figure S5). Given the 
observed increase in APOE expression following 
PPARβ/δ knockdown in vitro, apoE protein deposition 
was determined by immunolocalization in retinal 
sections. ApoE immunoreactivity was found to be 
increased within Bruch’s membrane and sub-RPE 
deposits in Pparβ/δ–/– mice compared to Pparβ/δ+/+ 
controls (Figure 3, N, O and P). RPE autofluorescence, 
which reflects lipofuscin accumulation, was also 
examined and found to be significantly higher 
throughout retinal sections of Pparβ/δ–/– mice as 
compared to age-matched Pparβ/δ+/+ mice (Figure S6). 
Interestingly, evaluation of visual function revealed that 
the average electroretinographic (ERG) responses from 
14-16 month old dark-adapted Pparβ/δ–/– and Pparβ/δ+/+ 
controls displayed identical dark-adapted a-wave 
responses, but a slight increase in sensitivity of b-wave 



































and B). Examination of the localization of markers for 
inner retinal cells including photoreceptors and bipolar 
cells by immunohistochemistry failed to demonstrate any 
gene specific differences (Figure S7, C and D). Overall, 
these data highlight that PPARβ/δ is essential for the 
outer retina at the level of the RPE cells, and may 
regulate sub-deposit formation and RPE degenerative 
changes as seen in the early stages of dry AMD. 
 
PPARβ/δ promotes laser-induced CNV 
 
Since PPARβ/δ knockdown in both RPE and choroidal 
endothelial cells in vitro resulted in an anti-angiogenic 
phenotype, the role of PPARβ/δ in development of 
CNV in vivo was examined. No evidence of 
spontaneous CNV or overt vascular changes were 
observed in aged Pparβ/δ–/– mice. However, laser-
induced CNV lesions in 18-20 month old Pparβ/δ–/– 
were smaller as compared to those observed in 







































GS‐IB4  (ON, optic nerve). Representative  images  from  three eyes/genotype are shown  to demonstrate  individual and merged CNV 







































Additionally, examination of the distribution of the 
lesions in flatmounts of the posterior eye cups revealed 
a genotype-dependent difference in the number of 
mouse eyes with single versus merged lesions. 
Specifically, while Pparβ/δ+/+ mice presented with two 
or three merged lesions, no eyes from the Pparβ/δ–/– 
cohort presented with three merged lesions, and only 
one eye displayed two merged lesions (Figure 4B). 
Quantitatively, measurement of CNV lesion volume 
determined from z-stacks and three-dimensional 
reconstructions confirmed a significantly smaller 
volume in Pparβ/δ–/– mice compared to Pparβ/δ+/+ mice 
(Figure 4D). These data demonstrate a functional role 
for the PPARβ/δ gene in angiogenesis and the 
development of CNV lesions.  
 
PPARβ/δ regulates extracellular matrix deposition 
and immune cell infiltration in CNV lesions 
 
PPARb/d has been shown to regulate extracellular 



































cellular matrix deposition and immune cell localization 
within CNV lesions from aged Pparβ/δ+/+ and Pparβ/δ–
/– mice were characterized by examining cross sections 
of the retina/RPE/choroid. Collagen type 4 (COL4) and 
fibronectin (FN1) are known components of Bruch’s 
membrane, sub-RPE deposits [32-34], and associated 
with CNV lesions [33]. Furthermore, fibronectin is 
known to be produced in response to vessel injury [35]. 
Quantitatively, significantly lower staining intensity for 
both COL4 and FN1 in CNV lesions was measured in 
aged Pparβ/δ–/– mice compared to age-matched 
Pparβ/δ+/+ controls (Figure 5, A and B).  As mentioned 
earlier, PPARβ/δ is known to influence inflammation 
[31], and this is one of the major pathways that 
regulates the pathogenesis of AMD [29, 36]. Thus, 
cross sections of the retina/RPE/choroid containing 
CNV lesions were probed with antibodies to ionized 
calcium binding adaptor molecule 1 (Iba1), which labels 
microglial cells and macrophages, and adhesion G 
protein-coupled receptor E1, also known as F4/80, 
which labels mature macrophages (Figure 5 C and S8). 
Figure 5. PPARβ/δ regulates extracellular matrix deposition and  immune‐cell  infiltration  in CNV  lesions.  (A)
FN1 (green) and COL4 (red) immunolocalization in CNV lesions of Pparβ/δ+/+ and Pparβ/δ−/− mice (dotted oval demarcates
the  lesion area; nuclei are  stained blue with Hoechst;  representative  images are  shown; scale bar = 50 µm).  (B) FN1 and
COL4 staining intensity was quantified in the CNV lesions of Pparβ/δ+/+ and Pparβ/δ−/− mice using ImageJ (mean and S.E.M.;
n = 3/group;  **p < 0.01,  two  tailed  t‐test).  (C)  Laser CNV  lesions  from Pparβ/δ−/− mice display  a higher number of  F4/80
(green) and Iba1 (red) immunopositive cells (dotted oval demarcates the lesion area; nuclei are stained blue with Hoechst;
representative  images  are  shown;  scale  bar = 50 µm).  (D)  The  numbers  of  F4/80+  and  Iba1+  cells  in  the  CNV  lesions  of
Pparβ/δ+/+ and Pparβ/δ−/− mice were counted using ImageJ (mean and S.E.M.; n = 3/group; *p < 0.01, two tailed t‐test).  
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Interestingly, a significant increase in the localization of 
both F4/80+ and Iba1+ cells within the neovascular 
lesions of Pparβ/δ–/– mice as compared to age-matched 
Pparβ/δ+/+ controls was quantified (Figure 5 D and S8). 
This is a noteworthy observation given the distinct 
phenotypes that macrophages can differentiate into: 1) 
the broadly characterized M1 macrophage, which is 
reported to contribute to pro-fibrotic and pro-
inflammatory phenotypes, and 2) M2 macrophages, 
which also have 4 different subtypes; [37] characterized 
as having immunosuppressive and tissue remodeling 
properties [19, 38].  This finding warrants future 
detailed analysis of the polarity of macrophages in the 
Pparβ/δ–/– CNV lesions. Combined, these results show 
that the loss of PPARβ/δ expression causes decreased 






































acute immune cell infiltration within small CNV 
lesions, and may reflect decreased fibrosis modulated 
by PPARβ/δ. 
 
Pharmacological antagonism of PPARβ/δ inhibits 
endothelial cell migration and tube formation in 
vitro 
 
Cellular organization is a central process in 
neovascularization, which involves endothelial cell 
migration and tube formation [39, 40]. Since disruption 
of the PPARβ/δ gene caused smaller CNV lesions in 
vivo, whether pharmacological antagonism of PPARβ/δ 
could inhibit angiogenesis, using functional assays 
measuring endothelial migration and tube formation, 












































(10 μM). (B) The cells migrating  into the wound were counted using  ImageJ (mean and S.E.M.; n = 3;   a, p < 0.01 relative to
Ctrl; b, p < 0.01 relative to bFGF, one way ANOVA, Tukey’s multiple comparisons test). (C) The effect of  ligand activation or
antagonism of PPARβ/δ on bFGF‐induced tube formation  in RF/6A cells was analyzed by an angiogenesis assay  in Geltrex™
(n = 3;  representative  images  at  t = 3 hours  are  shown). Ctrl: media only, bFGF: basic  fibroblast  growth  factor  (10  μg/ml),
bFGF+GW: bFGF plus GW0742 (10 μM), bFGF+GSK0660: bFGF plus GSK0660 (10 μM). Suramin, an inhibitor of tube formation,
was  used  as  a negative  control  (data  not  shown).  (D) Quantification  of  tube  length  in Geltrex™  using  ImageJ  (mean  and
S.E.M.; n = 3;  a, p < 0.01 relative to Ctrl; b, p < 0.01 relative to bFGF, one way ANOVA, Tukey’s multiple comparisons test). 
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was used to induce migration in a scrape wound assay 
in cultures of choroidal endothelial cells in the presence 
of the PPARβ/δ agonist, GW0742 or the PPARβ/δ 
antagonist GSK0660 (Figure 6A). Choroidal endothelial 
cell migration into the wound was inhibited by 
antagonism of PPARβ/δ with GSK0660 (Figure 6, A 
and B), while ligand activation of PPARβ/δ with 
GW0742 did not influence cell migration. The effect of 
ligand activation and pharmacological antagonism of 
PPARβ/δ on the ability of endothelial cells to form a 
three-dimensional network, indicative of vascular 
morphogenesis was also assessed (Figure 6C). 
Similarly, pharmacological antagonism of PPARβ/δ 
with GSK0660 inhibited tube formation (tube length) in 
choroidal endothelial cells compared to control and 
growth factor induced tube formation, whereas ligand 







































(Figure 6, C and D). In cell viability assays no 
significant differences were seen between control and 
PPARβ/δ agonist or antagonist-treated endothelial cells, 
indicating that the changes in cell migration and tube 
formation are not due to PPARβ/δ agonist or antagonist-
induced cell-death (Figure S9).  
 
Pharmacological antagonism of PPARβ/δ attenuates 
CNV lesions in vivo 
 
The therapeutic potential of inhibiting PPARβ/δ activity 
on CNV formation in 12-13 month old aged Pparβ/δ+/+ 
mice following experimentally induced laser injury to 
the back of the eye was examined. Mice were treated 
with vehicle control, GW0742 (0.5 mg/kg/day) or 
GSK0660 (1 mg/kg/day) (Figure 7A). The distribution, 








































old  C57BL/6J  (Pparβ/δ+/+) mice  subjected  to  laser  CNV  and  treated with  vehicle  control  (1%  DMSO  in  saline), GW0742  (0.5
mg/kg/day, i.p.), and GSK0660 (1 m/kg/day, i.p.) and stained with isolectin‐GS‐IB4 (n=10 eyes/group, 40 lesions; ON, optic nerve).
Representative  images  from  three eyes/treatment are  shown  to demonstrate  individual and merged CNV  lesions  (dotted and
solid  line  circles  demarcate  lesions  and ONs,  respectively).  (B) Distribution  of  number  of  eyes with  individual  versus merged
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rior eye-cups stained with isolectin GS-IB4 were 
assessed. A treatment dependent difference in the 
distribution of merged lesions was observed. 
Antagonism of PPARβ/δ with GSK0660 caused a 
higher proportion of individual neovascular lesions as 
compared to vehicle or agonist treated mice (Figure 
7B). Additionally, the area and volume of the lesions 
from animals treated with the PPARβ/δ antagonist were 
significantly lower relative to vehicle control and 
PPARβ/δ agonist treated mice (Figure 7, C and D). 
Finally, examination of cross-sections of the 
retina/RPE/choroid containing CNV lesions revealed 
decreased deposition of COL4 within the lesions of 
mice treated with the PPARβ/δ antagonist, while no 
difference was observed in the distribution of FN1 
(Figure 8, A, B and C). Interestingly, this acute 
treatment with agonist and antagonist did not effect the 
distribution of Iba1+ and F4/80+ cells within the 
neovascular lesion of aged Pparβ/δ+/+ mice (data not 
shown). Noteworthy, this short-term treatment with 
PPARβ/δ agonist or antagonist, also, did not affect the 

































Overall, these results are consistent with the in vitro 
studies and demonstrate that inhibition of PPARβ/δ 
activity results in a less severe CNV phenotype and may 





These studies demonstrate for the first time a role of 
PPARβ/δ in regulating different aspects of extracellular 
matrix turnover, angiogenesis, inflammation, and lipid 
processing in the eye. PPARβ/δ affects the RPE and 
choroidal endothelium differentially, selectively 
impacting the development of several fundamental 
AMD phenotypes. These data show that PPARβ/δ 
activity is functionally important in RPE and choroidal 
endothelial cell models systems; cells that are 
compromised during the initiation and progression of 
AMD. Knockdown of PPARβ/δ expression led to 
upregulation of extracellular matrix gene expression in 
primary RPE cells but a downregulation in choroidal 


































Figure 8.   Antagonism of PPARβ/δ decreases accumulation of collagen  type 4  in CNV  lesions.  (A) FN1  (green) and
COL4 (red) immunolocalization in CNV lesions of mice treated with vehicle control (1% DMSO in saline), GW0742 (0.5mg/kg/day,
i.p.), or GSK0660 (1m/kg/day, i.p.) (dotted oval demarcates the lesion area; nuclei are stained blue with Hoechst; representative
images are  shown;  scale bar = 50 µm).  (B) COL4 and  (C) FN1  staining  intensity was quantified  in  the CNV  lesions using  ImageJ
(Mean and S.E.M.; n = 3/group; *p < 0.01; ns: not significant, one way ANOVA, Tukey’s multiple comparisons test). 
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dependent downregulation of the expression of factors 
critical for angiogenesis, including VEGFA, PDGFRB 
and TGFB, in both cell populations, supports the 
hypothesis that PPARβ/δ regulates signaling pathways 
important in development of neovascular lesions. 
Consistent with the in vitro studies, a significant decrease 
in area and volume of laser induced neovascular lesions 
was observed in both aged Pparβ/δ-/- mice and in 
Pparβ/δ+/+ mice following pharmacological antagonism 
of the receptor. In contrast to these findings, morpho-
logical characterization of the ocular phenotype of aged 
Pparβ/δ–/– mice revealed the exacerbation and 
development of several features of the early dry AMD 
phenotype including continuous sub-RPE deposits, 
increased RPE autofluorescence, Bruch’s membrane 
thickening, RPE pigmentary changes and disorganized 
basal infoldings. These in vivo results are supported by in 
vitro data demonstrating increased dysregulation of 
extracellular matrix molecules following PPARβ/δ 
knockdown in human RPE cells. Collectively, these 
studies illustrate, for the first time, cell-specific effects of 
PPARβ/δ in two populations of AMD vulnerable cells 
(Figure 9). Our findings correlate with the concept of 
selective modulation of PPARs and other nuclear 
receptors such as the estrogen receptor, in which ligand 
binding may lead to differential gene expression and 
biological responses in different cells and tissues [41, 
42]. Additionally, part of the variability observed in the 
eye, may be due to differential expression of PPARβ/δ in 
the RPE versus choroidal endothelial cells (Figure 1A); 
differential expression of the receptor co-regulatory 
proteins including co-activators and co-repressors; 
differential binding affinities of the co-regulatory 
proteins; and/or varying receptor conformational changes 
induced by endogenous ligand binding in epithelial 
versus endothelial cells [43]. This is an area of ongoing 
investigation.  
 
The increased influx of immune cells within the 
neovascular lesion in the absence of PPARβ/δ 
expression is an interesting finding that requires further 
investigation and may be clarified with full 
characterization of the polarization status of these 
immune cells. Recently, PPARβ/δ has been shown to be 
involved in alternative activation of macrophages in 
mice [44]. Reportedly, both IL-13 and IL-4 induce 
expression of PPARβ/δ and modulate the ability of 
adipose tissue and liver macrophages to transition to the 
M2 phenotype. It has also been shown that PPARβ/δ 
coordinates the immune phenotype of alternatively 
activated macrophages, both in vitro and in vivo [45]. 
These reports suggest that the PPARβ/δ regulates 
macrophage polarization in animal models of liver-
injury and atherosclerosis. However, it is important to 
note that to date, no one has critically examined the 
specific subtype of M2 macrophages actually regulated 
by PPARβ/δ, and since different subtypes have different 
functions [37], the precise effect of this particular 
change requires further investigation. Based on these 
studies it is plausible that the population of Iba1+ cells 
observed in the CNV lesions of Pparβ/δ–/– mice are 
transient and may express markers of the alternatively 
activated macrophage phenotype, which are involved in 
immunosuppression and tissue remodeling [19, 38]. 
CNV lesions in Pparβ/δ–/– mice also displayed a 
reduced deposition of COL4 and FN1 in the lesion 
supporting a decrease in fibrosis. This is a major factor 
in responsiveness to anti-VEGF treatment for neo-
vascular AMD [46, 47]. To our knowledge this is the 
first study to report the involvement of the PPARβ/δ 























To date, no differences in PPARβ/δ expression between 
normal and AMD cohorts have been reported. This may 
be due to the fact that evaluating the activity of 
PPARβ/δ along with expression of co-factors and 
specific target genes is more informative than 
measuring expression of the receptor in silos. 
Nevertheless, the purported role of PPARβ/δ in other 
tissues [13, 48-50] in combination with our data from 
PPARβ/δ knockdown in vitro, and genetic ablation in 
vivo, gave rise to the hypotheses that pharmacologic 
targeting of PPARβ/δ may therapeutically improve 
choroidal neovascularization and lipid accumulation. To 
test our first hypothesis, the postulate that pharmaco-
logic antagonism of PPARβ/δ could therapeutically 
improve choroidal neovascularization, the effect of 
ligand activation and pharmacological antagonism of 
PPARβ/δ on endothelial migration and tube formation 
Figure 9. Summary model of selective regulation of dry and 
wet AMD related pathogenic pathways by PPARβ/δ in AMD 
vulnerable  cells.  Ligand  activation  of  PPARβ/δ  inhibits  lipid 
accumulation by RPE cells and may have  therapeutic effect  in dry‐
AMD.  In  contrast,  antagonism  of PPARβ/δ  inhibits neovasculariza‐
tion possibly by regulating inflammation and fibrosis in outer‐retina. 
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in the choroidal endothelial cell line, RF/6A was 
determined. Pharmacological antagonism of PPARβ/δ 
activity inhibited choroidal endothelial cell migration as 
well as tube formation in a three-dimensional matrix. 
By contrast, ligand activation of PPARβ/δ had no effect 
in these angiogenesis assays. These results are 
consistent with previous studies by others using human 
retinal microvascular endothelial cells and a rat model 
of oxygen-induced retinopathy [51]. Modeling retinal 
neovascularization, it was shown that pharmacological 
antagonism of PPARβ/δ significantly decreased serum-
induced retinal endothelial cell proliferation and tube 
formation in a dose-dependent manner, and in vivo 
decreased retinal neovascularization in young rats. 
Another study from the same group showed that 
pharmacological antagonism of PPARβ/δ stabilized 
tight junctions in retinal microvascular endothelial cells 
treated with VEGF, and reduced VEGFR1/2 expression, 
suggesting a role in retinal vascular permeability [52]. 
The present study examined the effect of ligand 
activation and pharmacological antagonism of PPARβ/δ 
on choroidal neovascularization, in which the highly 
fenestrated choriocapillaris; vasculature supporting the 
outer retina; grow through Bruch’s membrane under the 
RPE, in vivo, using a laser-induced CNV model. 
Antagonism of PPARβ/δ provided a therapeutic effect 
on laser-induced lesion formation, whereas ligand 
activation of PPARβ/δ had no effect, similar to results 
obtained from our in vitro analyses. Interestingly, 
antagonizing PPARβ/δ activity did not negatively 
impact the integrity of the RPE cell tight junctions. This 
may be due to the fact that antagonism of PPARβ/δ was 
acute rather than long term. Equally likely is that 
genetic ablation of the receptor (as seen in vivo in our 
mice, but not reported in humans) is detrimental to the 
RPE cells rather than receptor antagonism itself. 
 
Our second hypothesis supports the notion that it is 
critical to investigate the therapeutic potential of 
targeting PPARβ/δ activity in the pathogenesis of dry 
AMD. Specifically, whether PPARβ/δ activity can be 
targeted for removal of lipid-rich deposits within 
Bruch’s membrane and sub-RPE deposits should be 
examined in more detail. Several studies have found 
that ligand activation of PPARβ/δ inhibits lipid 
accumulation as well as expression of pro-inflammatory 
cytokines in THP-1 macrophages and mouse monocytes 
[53, 54]. Though, the sub-RPE deposits in the aged 
Pparβ/δ–/– mice contain apoE, they did not stain 
positively for oil red o or filipin and do not appear to 
contain neutral lipids or cholesterol (data not shown). 
As proof of concept, using an in vitro model of lipid-
loaded RPE cells, it was found that ligand activation of 
PPARβ/δ decreased lipid accumulation. Taken together, 
these results support the need to test the effect of 
PPARβ/δ agonists in conditions where there are 
systemic and/or dietary factors contributing to 
development of early AMD. Though there is selective 
modulation of the PPARβ/δ in RPE and choroidal 
endothelial cells, based on the in vitro and in vivo data, 
ligand activation of PPARβ/δ is beneficial to RPE cells 
and does not appear to have a negative impact on 
healthy choroidal endothelial cells. Currently there are 
no FDA-approved PPARβ/δ drugs, but the recent 
development of highly specific and selective agonists 
and antagonists [selective PPARβ/δ modulators 
(SPPARMs)] such as GW501516, GW0742, GSK0660 
and GSK3787 have led to improved approaches to study 
the PPARβ/δ pathway in disease models including 
obesity and atherosclerosis [55]. In future studies, it will 
be imperative to construct PPARβ/δ-selective drug-dose 
response curves to describe cell-selective responses in a 
quantitative manner and test the suitability of 
pharmacological agents in long-term studies using aged 
animal models of AMD that develop lipid accumulation 
within Bruch’s membrane.  
 
This is the first study to report on the PPARβ/δ pathway 
in RPE and choroidal endothelial cells and its potential 
role in the pathogenesis of AMD. The results indicate, 
for the first time, selective modulation of a nuclear 
receptor in the eye. Specifically, that inhibition of 
PPARβ/δ activity may successfully attenuate neovascu-
lar lesion formation concomitant with decreased 
expression of extracellular matrix molecules and 
decreased angiogenic factors, in vivo, while activation 
of PPARβ/δ activity may target lipid accumulation. The 
results of this treatment may be attributable to PPARβ/δ 
regulation of several distinct AMD pathogenic 
pathways: fibrosis, inflammation and lipid metabolism. 
The Pparβ/δ–/– mice also displayed early dry AMD like 
pathology, establishing these mice as a model to further 
study the initiation and progression of the early sub-type 
of the disease. Additional studies should be conducted 
to study the contribution of other PPARβ/δ regulatory 
pathways that may influence disease pathology and the 
therapeutic potential of selectively targeting PPARβ/δ 
as a means to inhibit inflammation, fibrosis and lipid 
accumulation (Figure 9). 
 




RF/6A cells, a spontaneously transformed choroidal 
endothelial cell line derived from the eyes of a rhesus 
macaque fetus, passages 35–40, and ARPE19 cells, a 
spontaneously arising human RPE cell line derived 
from the eyes of a 19 year-old male donor, passages 21–
28, were obtained from ATCC (Manassas, VA, USA). 
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Primary cell cultures used included RPE cells (1° RPE) 
isolated from donor eyes older than 60 years (n=3), 
collected from the North Carolina Organ Donor and Eye 
Bank Inc. in less than 6  hours post-mortem and 
cultured within 24 hours in accordance with the 
Declaration of Helsinki for research involving human 
tissue, as previously described [56]. Donor eyes did not 
reveal any evidence of retinal/RPE changes upon post-
mortem evaluation of the posterior eye under a 
dissecting microscope. Only passages between 4 and 9 
of each of the primary RPE cell cultures were used in 
this study. Final conditions of both ARPE19 and the 
primary RPE cell cultures were such that cells were 
post-confluent and demonstrated zonula occludens 
positive immunoreactivity. 
 
Transcriptional activation assay 
 
The transcriptional activity of PPARβ/δ was measured 
using a luciferase-based reporter assay and PPARβ/δ 
target gene expression was quantified using qPCR. 
Briefly, 50000 human primary RPE cells, ARPE19 cells 
or RF/6A cells/well were seeded in 24-well plates in 
phenol red-free medium supplemented with 7.5% 
charcoal-stripped FBS and cultured overnight. 
Lipofectin (Invitrogen)-mediated transfection was 
performed the following day, using plasmids encoding a 
DR-1 luciferase reporter, CMV-β galactosidase or 
pBSII, as described previously [57, 58]. After overnight 
culture, cells were transfected with small interfering 
RNAs (siRNA) (scrambled control siRNA or an siRNA 
against PPARβ/δ; [100 pmoles per 250,000 cells]); 5 
hours after knock-down, the transfected cells were 
treated with PPARβ/δ agonist and antagonist at doses 
listed in Table S1. The cells were lysed 24 hours later 
for luminescence reading. Luciferase (reporter) and β-
galactosidase [chlorophenol red β-d-galactopyranoside 
(CPRG) as substrate; transfection normalization] 
activities were measured using a Perkin-Elmer fusion 
instrument. Concomitantly, cells were treated with these 
same compounds for RNA isolation and target gene 
expression studies. All samples were run in triplicate 
and experiments were performed a minimum of three 
times. 
 
siRNA transfection and cell functional assays 
 
siRNAs were used to knock down PPARβ/δ in vitro. A 
control siRNA (siC) for a non-targeting sequence or 5 
different PPARβ/δ siRNAs (siPPARβ/δ, siPPARβ/δ1, 
siPPARβ/δ2, siPPARβ/δ3, siPPARβ/δ4; GE 
Dharmacon, Lafayette, CO, USA; Table S2) were trans-
fected into cells using Lipofectamine RNAiMAX 
(Invitrogen, Grand Island, NY, USA) and tested to 
account for non-specific targeting of the siRNA (Figure 
S11). Briefly, complexes of siRNA (100 pmoles per 
250,000 cells) and RNAiMAX in OPTI-MEM were 
added to six-well cell-culture plates according to the 
manufacturer’s protocol.  siPPARβ/δ was used in 
subsequent experiments. ARPE19, 1° RPE or RF/6A 
cells (250 000 cells/well) were added to each well, 
along with DMEM/F12 or MEM supplemented with 
10% charcoal-stripped fetal bovine serum (CS-FBS) for 
ARPE19 or 1° RPE, and endothelial cells, respectively. 
Cells were used 24 hours post-transfection, in cell 
viability assays, scrape wound migration assays (MEM 
1% CS-FBS), tube-formation assays (MEM 1% FBS) 
and PPAR activity assays (7.5% CS-FBS), as described. 
RNA was extracted at the indicated time points for 
quantitative real-time PCR (qPCR). Primer sequences 
are provided in Table S3.   
 
RNA Isolation and qPCR 
 
Total RNA isolation from cultured cells, freshly isolated 
human RPE cells and choroid; RNA quality assessment; 
cDNA reverse transcription; and qPCR were completed 
as previously described [59]. The purities of the freshly 
isolated human RPE cells and choroid from aged donor 
eyes were determined by measuring the expression 
levels of RPE specific markers including BEST1 and 
RPE65 and a vascular marker, PECAM. Minimal levels 
of cross contamination were found (Figure S12). qPCR 
was performed using the Bio-Rad CFX96 Realtime 
PCR Detection System (Bio-Rad). Melt curves for each 
pair of primers were inspected to confirm a single 
amplicon. The Ct values were normalized to a 
housekeeping gene (acidic ribosomal phosphoprotein 
P0, 36B4). Gene-expression fold changes were 
calculated using the ΔΔCT method. Primer sequences 
used were selected from Primer Bank, 
http://pga.mgh.harvard.edu/primerbank and are present-
ed in Supplementary Table S3. The amplification 
products obtained after qPCR using PPARβ/δ, RXRα, 
RXRβ, BEST1, RPE65, PECAM and 36B4 primers 





AdipoRed™ (Lonza, Walkersville, MD) assay was used 
to measure intracellular lipid accumulation according to 
manufacturer’s protocol. Briefly, human primary RPE 
cells were plated in a 96-well plate (10000 cells/well) in 
DMEM/F12 media with 7.5% charcoal stripped FBS. 
The cells were treated with different lipids (20μM) 
namely, α-linolenic acid (α-LA), docohexanoic acid 
(DHA), arachidonic acid (AA), and palmitic acid (PA) 
for 48 hours, followed by a 24 hour treatment with 
GW0742 (10 μM) and GSK0660 (10 μM). The cells 
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were then washed with PBS and treated with 
AdipoRed™ reagent. After 10 minute incubation, the 





Male and female Pparβ/δ+/+ and Pparβ/δ–/– mice on the 
C57BL/6 background [60], aged (Pparβ/δ+/+: n=13, 13 
females, 3 males; Pparβ/δ–/–: n=10, 7 females, 3 males) 
were maintained in a temperature (25 °C) and light 
controlled (12h light/12 h dark) environment and 
provided standard mouse chow ad libitum. Mice were 
screened for the confounding retinal degeneration 8 
mutation and its absence was confirmed as previously 




The study protocols were approved by the Duke 
University or Pennsylvania State University 
Institutional Animal Care and Use Committees. All 
animal experiments were performed in accordance with 
the guidelines of the ARVO statement for the Use of 
Animals in Ophthalmic and Vision Research. 
 
Immunohistochemistry and morphology 
 
For immunohistochemistry, eyes were fixed in 4% 
paraformaldehyde and cryopreserved. Specimens were 
cryosectioned from the superior cup through the optic 
nerve to the inferior cup in 10 µm increments. 
Cryosections from the nasal, central and peripheral 
regions of the eye were probed with antibodies (listed in 
Supplementary Table S4). Non-specific immuno-
staining in sections was blocked with normal serum 
(Jackson Immunoresearch, West Grove, PA, USA) 
appropriate to the secondary antibody species. 
Secondary antibodies were conjugated to AlexaFluor 
568 and 488 (Invitrogen). Control slides containing 
sequential sections were probed with non-immune 
serum and buffer without primary antibody. Nuclei 
were stained with Hoechst 33258 (Invitrogen). Images 
were collected on a Nikon C1 confocal microscope and 
visualized and processed using Nikon EZ-C1 Free 
viewer. 
 
Transmission electron microscopy 
 
For electron microscopy, eyes were fixed in 2% 
gluteraldehyde, post fixed in 1% osmium tetroxide, and 
embedded in Spurrs resin. Morphology of the 
retina/RPE/choroid was studied in 1 μm toluidine blue 
stained plastic sections. The length of deposits/RPE 
length was calculated and plotted for Pparβ/δ+/+ and 
PPARβ/δ−/− mice (10 images per mice, n=4 mice per 
genotype). Incidence of pathology in PPARβ/δ−/− eyes, 
including RPE abnormalities (seen in greater than 20% 
of the eye), presence of sub-RPE deposits, and thickness 
of Bruch’s membrane, were evaluated in electron 
microscopy thin sections (10 images per mouse, n = 4 




ERGs were recorded using the Espion E2 system 
(Diagnosys LLC) as described previously [56]. Briefly, 
14-16-mo-old Pparβ/δ+/+ and  PPARβ/δ−/− mice were 
dark-adapted for four hours and anesthetized by an i.p. 
injection of a ketamine/xylazine mixture (85/10 mg/kg). 
Pupils were dilated with 1% cyclopentolate-HCl and 
2.5% phenylephrine, and the mouse body temperature 
was maintained at 37 °C using a water-based warming 
pad. ERG responses under dark-adapted (“scotopic”) 
conditions were evoked by a series of nine flashes 
ranging from 0.0001 cd·s/m2 to 100 cd·s/m2. For flashes 
up to 0.1 cd·s/m2, responses of 10 trials were averaged. 
For 0.5 and 1 cd·s/m2 flash responses, three trials were 
averaged. For brighter stimuli, responses to single 
flashes were recorded without averaging. Light-adapted 
(“photopic”) ERGs were evoked by a series of six 
flashes ranging from 0.2 cd·s/m2 to 2,000 
cd·s/m2 whereas rod inputs were suppressed with a 
steady background illumination of 50 cd/m2. Up to 10 
trials were averaged for all flash responses. Analysis of 
a- and b-wave amplitudes was performed as described 
[56]. 
 
Mouse model of CNV 
 
Laser photocoagulation was performed in cohorts of 18-
20 month old Pparβ/δ+/+ (n=7, all females) and 
PPARβ/δ−/− mice (n=4, 3 females, 1 male), as 
previously described [59]. Briefly, four thermal burns 
were induced in each eye around the optic nerve, using 
a slit lamp delivery system. The mice were euthanized 3 
weeks after laser treatment and the eyes were harvested 
for visualization of laser-induced CNV in posterior pole 
flat-mounts, or cryopreserved for immunohisto-
chemistry and morphology experiments. To test the 
efficacy of PPARβ/δ drugs, 12-13-month old Pparβ/δ+/+ 
mice were divided into three cohorts (n=10/cohort, 5 
females and 5 males per cohort), vehicle control (1% 
DMSO in saline), GW0742 (0.5 mg/kg/day, i.p.) [61, 
62] and GSK0660 (1 mg/kg/day, i.p.) [63]. Animals 
were pre-treated with the drugs for 2 days prior to laser 
CNV induction and euthanized 10 days later.  CNV 
lesion volume, area and size were measured in flat-
mounts stained with isolectin GS-IB4 to examine 
vascularity of the neovascular lesion. 
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Evaluation of mouse CNV lesions 
 
Following laser CNV, flatmounts of the posterior pole 
were stained with isolectin GS-IB4 Alexa Fluor® 
conjugate (Life Technologies, Grand Island, NY) 
according to manufacturer’s protocol, to examine 
vascularity and size of the neovascular lesion, and 
visualized by a Zeiss Axiolan 2 (Carl Zeiss, Thornwood, 
NY) fluorescent microscope. Horizontal optical section 
images of the flatmounts were obtained at 1.50 µm 
intervals. CNV lesion thickness was measured using 
Nikon EZ-C1 viewer software. Total area of the CNV 
lesions per lesion per animal was measured using ImageJ 
software (developed by Wayne Rasband, National 
Institute of Health, Bethesda, MD) and the volume of the 
lesions was measured by running the MeasureStacks 
script in ImageJ. All measurements were normalized to 
Pparβ/δ+/+ or vehicle control in their respective 
experiment. Cryosections from the lasered eyes were 
screened for lesions and stained with F4/80 and Iba1 
antibodies (Supplementary Table S4). CNV was 
demarcated and cells staining positive for F4/80 and Iba1 
were counted and plotted. To study extracellular matrix 
deposition, cryosections were stained with FN1 and 
COL4 antibodies. CNV lesions were demarcated and 
mean fluorescence intensity of FN1 and COL4 was 
measured by ImageJ. Mean intensity was plotted. 
 
Scrape wound migration assay 
 
Following PPARβ/δ knock-down in RF/6A cells by 
siRNA transfection, as described in the main text, 
250000 cells were added to each well in six-well plates; 
24 hours after knock-down, the cell monolayer was 
scraped in a direction perpendicular to a horizontal line, 
using a 1000 µl pipette tip, to create a wound. bFGF 
(100 ng/ml)-induced cell motility was observed at t = 0 
and 36 hours post-scraping. The total number of cells 
migrating into the wound at t = 36 were counted using 
ImageJ and normalized to control siRNA. Similarly 
RF/6A cells were pretreated with PPARβ/δ agonist, 
GW0742 or antagonist, GSK0660, at doses listed in 
Table S1 for 24 hours. It was followed by scrape wound 
assay. Data were  generated  from  four  fields  of  view/ 




Tube formation assay was used as a model for 
angiogenesis. Geltrex™ (Life Technologies, Grand 
Island, NY, USA) was thawed overnight at 4°C. Using 
cold pipette tips, 200 μl/well was added in a 12-well 
plate. The Geltrex solidified into a thin layer after 
incubation at 37°C for 1 hour. PPARβ/δ was knocked 
down in RF/6A endothelial cells by siRNA transfection, 
trypsinized after 48 hours and plated onto the Geltrex-
coated wells (2.5 × 104 cells/well). Network formation 
was examined after 3 hours, using an inverted phase-
contrast microscope, and quantified as total tube length 
formed by siPPARβ/δ-endothelial cells normalized to 
siControl, using ImageJ. Similarly RF/6A cells were 
pretreated with PPARβ/δ agonist, GW0742 or antagonist, 
GSK0660, at doses listed in Table S1 for 24 hours 
followed by scrape wound assay. Four fields of 
view/experiment were examined, in a total of three 
biological replicates. 
 
Cell viability and proliferation assays 
 
Primary human RPE, ARPE19, and RF/6A cells were 
plated in 96-well plates at different cell densities (5000-
, and 10000-cells per well) and treated with DMSO, 
GW0742 (10μM) and GSK0660 (10μM). Cell viability 
was measured after four days post-plating using 
CellTiter-Blue® (Promega, Madison, WI), according to 
the manufacturer’s protocol. The results obtained from 




A Leica Spectral Laser Scanning Confocal Microscope 
was used to measure autofluorescence throughout the 
entire RPE layer of 18-mo-old PPARβ/δ-/- and 
Pparβ/δ+/+ cryosections (n = 3 sections per mouse, n = 3 
mice per genotype) as previously described [64]. The 
three sections were selected randomly from the nasal, 
central, and temporal regions of the mouse eye. Lambda 
(λ) scans were performed using a 405-nm laser. 
Excitation and emission frequencies were measured 
with a 5-nm-wide band through a spectral range from 
422.5 nm to 722.5 nm using serial 30-image scans at 
׽10.3-nm intervals. Fluorescent intensities are 
represented as arbitrary units as defined by the confocal 
Leica software. The significance of differences in 
spectra obtained between PPARβ/δ-/- and Pparβ/δ+/+ 
mice was assessed using a two-tailed t test, with no 




Statistical methods for data analysis included two-tailed 
Student's t-test and two-way ANOVA, with Sidak's 
multiple comparison test using GraphPad Prism. Values 
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Figure  S2.  PPARβ/δ  agonist  and  antagonist  treatment  of AMD  vulnerable  cells  in  the  absence  of  transfection
differentially effect  receptor  target gene expression. Human primary RPE  (1°RPE);  (A), ARPE19  (B), and RF/6A  (C)  cells
were  treated with GW0742  (10μM) and GSK0660  (10μM)  for 24 hours, using DMSO as  control. mRNA  levels of  the PPARβ/δ
target genes ANGPTL4 and PDK4 were measured using qRT‐PCR (n=3, p<0.05). 
Figure S1. PPARβ/δ signaling pathway  is functional  in ARPE19 cells.  (A) PPARβ/δ activity  in ARPE19 cells transfected
with  the  DR1  luciferase  reporter  and  siC  or  siPPARβ/δ;  cells were  treated with  PPARβ/δ  agonist,  GW0742  or  antagonist,


















































































































Figure  S4.  Quantification  of  thickness  of
retinal  layers  of  Pparβ/δ+/+  and  Pparβ/δ−/−
mice. Toluidine blue stained retinal sections were
imaged  from  age  matched  Pparβ/δ+/+  (n=3)  and
Pparβ/δ−/− (n=2) mice at 20X from end to end and
images  were  tiled  to  create  complete  retinal
section  images.  Six  equidistant measurements  of
(A) outer nuclear  layer  (ONL)  (B), outer plexiform
layer  (OPL),  (C)  inner  nuclear  layer  (INL),  and  (D)
inner plexiform  layer (IPL) towards each end were
made from the optic nerve. The thickness of these
layers  was  plotted.  Tiled  images  demonstrating
overall retinal morphology of (E) Pparβ/δ+/+ and (F)
Pparβ/δ−/− mice. 





































































































































































































































































































































































Figure  S9.  Ligand  activation  or  pharmacological  antagonism  of  PPARβ/δ  does  not  affect  cell  viability  in  cell‐
culture models.  Cell  viability was measured  after  a  4  day  treatment with  the  PPARβ/δ  agonist,  GW0742  or  antagonist,
GSK0660 in (A) primary RPE cells, (B) ARPE19 and (C) RF/6A cells. 
Figure S10. Ligand activation or pharmacological antagonism of PPARβ/δ does not affect RPE  tight  junctions  in vivo.































































































































siRNA Company Catalog# 
siC Qiagen 1027281 
siPPARβ/δ Dharmacon L-003435-00-0005 
siPPARβ/δ1 Dharmacon J-003435-06 
siPPARβ/δ2 Dharmacon J-003435-07 
siPPARβ/δ3 Dharmacon J-003435-08 
siPPARβ/δ4 Dharmacon J-003435-09 
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Figure  S12.  Freshly  isolated  RPE  and  choroid  from  human  donor  eyes  have  minimal  cross










































































































Antibody/Stain Source Dilution 
Apolipoprotein E (ApoE) 










Phalloidin Tetramethylrhodamine B isothiocyanate 
Millipore 
Millipore 
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  Table S3. List of primers. 
 
Gene Primers Sequence 5’→3’ Human 
36B4 
 
ANGPTL4 
 
BEST1 
 
COLA1 
 
COL4A4 
 
FN1 
 
PDGFRB 
 
PDK4 
 
PECAM1 
 
PPARD 
 
RPE65 
 
RXRA 
 
RXRB 
 
SERPINF1 
 
TGFB1 
 
VEGFA 
 
VTN 
 
Forward 
Reverse 
Forward 
Reverse 
Forward  
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
GGACATGTTGCTGGCCAATAA 
GGGCCCGAGACCAGTGTT 
GTCCACCGACCTCCCGTT A 
CCTCATGGTCTAGGTGCTTGT 
AACTGAGCCTACCACACAACA 
CGGATTCGACCTCCAAGCC 
TCACCAGGACAGAAGGGAAG 
CTCTGGCACCTTTTGCTAGG 
CTGGATTTGGAGAACGTACCG 
TGATCCAATTCTGCCTGCAC 
ATGATGAGGTGCACGTGTGT 
CTCTTCATGACGCTTGTGGA 
AGCACCTTCGTTCTGACCTG 
TATTCTCCCGTGTCTAGCCCA 
GGAGCATTTCTCGCGCTACA 
ACAGGCAATTCTTGTCGCAAA 
AACAGTGTTGACATGAAGAGCC 
TGTAAAACAGCACGTCATCCTT 
CCAACAGATGAAGACAGATGCA 
CTGAACGCAGATGGACCTCTA 
CCTGCTGGTGGTTACAAGAAA 
CCTGCCTGTTACATGAGCTGT 
GAGCCCAAGACCGAGACCTA 
AGCTGTTTGTCGGCTGCTT 
AGCCCCCAGATTAACTCAACA 
GATTGCACATAGCCGTTTGC 
TTCAAAGTCCCCGTGAACAAG 
GAGAGCCCGGTGAATGATGG 
CAATTCCTGGCGATACCTCAG 
AGATAACCACTCTGGCGAGTC 
AGGGCAGAATCATCACGAAGT 
AGGGTCTCGATTGGATGGCA 
CACTATGCCGGAGGATGAGT 
TCAGGATTCCCTTTGGACTG 
 
